US Patent 9539211 Ultra low density pulmonary powders
Patent 9539211 was granted and assigned to Civitas Therapeutics on January, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+387 characters)
Article
Patent abstract
The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 μm and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Michael M. Lipp0
Richard P. Batycky0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09539211 Ultra low density pulmonary powders US Patent 9539211 Ultra low density pulmonary powders
Infobox
Patent Number
095392110
Patent Number
95392110
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
095392110
Date of Patent
January 10, 2017
0Patent Application Number
147070710
Date Filed
May 8, 2015
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09539211 Ultra low density pulmonary powders
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09539211
Date of patent
January 10, 2017
Patent application number
14707071
Date Filed
May 8, 2015
Patent primary examiner
Find more entities like US Patent 9539211 Ultra low density pulmonary powders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.